<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Despite regular surveillance colonoscopy, the metachronous <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk for mismatch repair (MMR) gene mutation carriers after segmental resection for <z:hpo ids='HP_0003003'>colon cancer</z:hpo> is high and total or subtotal colectomy is the preferred option </plain></SENT>
<SENT sid="1" pm="."><plain>However, if the index <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is in the rectum, management decisions are complicated by considerations of impaired bowel function </plain></SENT>
<SENT sid="2" pm="."><plain>We aimed to estimate the risk of metachronous <z:hpo ids='HP_0003003'>colon cancer</z:hpo> for MMR gene mutation carriers who underwent a proctectomy for index <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: This retrospective cohort study comprised 79 carriers of germline mutation in a MMR gene (18 MLH1, 55 MSH2, 4 MSH6, and 2 PMS2) from the <z:hpo ids='HP_0003003'>Colon Cancer</z:hpo> Family Registry who had had a proctectomy for index <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Cumulative risks of metachronous <z:hpo ids='HP_0003003'>colon cancer</z:hpo> were calculated using the Kaplan-Meier method </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: During median 9 years (range 1-32 years) of observation since the first diagnosis of <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e>, 21 carriers (27 %) were diagnosed with metachronous <z:hpo ids='HP_0003003'>colon cancer</z:hpo> (incidence 24.25, 95 % confidence interval [CI] 15.81-37.19 per 1,000 person-years) </plain></SENT>
<SENT sid="6" pm="."><plain>Cumulative risk of metachronous <z:hpo ids='HP_0003003'>colon cancer</z:hpo> was 19 % (95 % CI 9-31 %) at 10 years, 47 (95 % CI 31-68 %) at 20 years, and 69 % (95 % CI 45-89 %) at 30 years after surgical resection </plain></SENT>
<SENT sid="7" pm="."><plain>The frequency of surveillance colonoscopy was 1 colonoscopy per 1.16 years (95 % CI 1.01-1.31 years) </plain></SENT>
<SENT sid="8" pm="."><plain>The AJCC stages of the metachronous <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, where available, were 72 % stage I, 22 % stage II, and 6 % stage III </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Given the high metachronous <z:hpo ids='HP_0003003'>colon cancer</z:hpo> risk for MMR gene mutation carriers diagnosed with an index <z:e sem="disease" ids="C0007113" disease_type="Neoplastic Process" abbrv="">rectal cancer</z:e>, proctocolectomy may need to be considered </plain></SENT>
</text></document>